4.0 Article

Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics

Journal

CIRCULATION-CARDIOVASCULAR GENETICS
Volume 8, Issue 1, Pages 192-206

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCGENETICS.114.000216

Keywords

genetics; lipoprotein; metabolomics; metabolism; risk assessment

Funding

  1. Academy of Finland
  2. TEKES-the Finnish Funding Agency for Technology and Innovation
  3. Sigrid Juselius Foundation
  4. Novo Nordisk Foundation
  5. Finnish Diabetes Research Foundation
  6. University of Oulu, Finland
  7. British Heart Foundation
  8. UK Wellcome Trust
  9. UK Medical Research Council via the University of Bristol Integrative Epidemiology Unit
  10. Medical Research Council [MC_UU_12013/1] Funding Source: researchfish
  11. Novo Nordisk Fonden [NNF13OC0005747] Funding Source: researchfish
  12. MRC [MC_UU_12013/1] Funding Source: UKRI

Ask authors/readers for more resources

Metabolomics is becoming common in epidemiology due to recent developments in quantitative profiling technologies and appealing results from their applications for understanding health and disease. Our team has developed an automated high-throughput serum NMR metabolomics platform that provides quantitative molecular data on 14 lipoprotein subclasses, their lipid concentrations and composition, apolipoprotein A-I and B, multiple cholesterol and triglyceride measures, albumin, various fatty acids as well as on numerous low-molecular-weight metabolites, including amino acids, glycolysis related measures and ketone bodies. The molar concentrations of these measures are obtained from a single serum sample with costs comparable to standard lipid measurements. We have analyzed almost 250 000 samples from around 100 epidemiological cohorts and biobanks and the new international set-up of multiple platforms will allow an annual throughput of more than 250 000 samples. The molecular data have been used to study type 1 and type 2 diabetes etiology as well as to characterize the molecular reflections of the metabolic syndrome, long-term physical activity, diet and lipoprotein metabolism. The results have revealed new biomarkers for early atherosclerosis, type 2 diabetes, diabetic nephropathy, cardiovascular disease and all-cause mortality. We have also combined genomics and metabolomics in diverse studies. We envision that quantitative high-throughput NMR metabolomics will be incorporated as a routine in large biobanks; this would make perfect sense both from the biological research and cost point of view - the standard output of over 200 molecular measures would vastly extend the relevance of the sample collections and make many separate clinical chemistry assays redundant.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available